Home › Friedreich Ataxia › NCT07444333

Cardiac Output and Fatigue in Friedreich's Ataxia

Who can join

All ages · All sexes

Inclusion Criteria:

1. Genetically confirmed FRDA
2. Ability to safely ride a stationary bicycle (mFARS sitting posture sub-score \<2)

Exclusion Criteria:

1. Beck depression score \>19, a score that precludes ability to exercise.
2. Montreal Cognitive Assessment (MoCA) score \<23/30
3. Disorders that interfere with ability to perform endurance exercise (e.g., stroke, respiratory problems, traumatic brain injury, or neuromuscular disease).
4. Regular participation in vigorous endurance exercise (defined as \>2 days/week for at least the past 4 months at max HR\>65%).
5. Evidence of serious arrhythmias or ischemic heart disease.

About the study

This is a clinical trial examining to impact of aerobic training plus omaveloxolone in FRDA. Thirty individuals with FRDA will be recruited; 20 individuals will be on omaveloxolone treatment whereas the other ten individuals will not. Individuals will undergo baseline assessment including cardiopulmonary exercise testing (CPET), mFARS, gait speed, Timed Up and Go (TUG), Fatigue Severity Scale (FSS), Fatigue Impact Scale (FIS), and 6-minute Walk Test (6MWT). Individuals will then perform 3-months of home aerobic training. Repeat assessments will be conducted at 3- and 6-months.

What is being tested

• Aerobic Exercise (behavioral)

Sponsor: Scott Barbuto · Participants: 30 · Started: Jul 15, 2026

Contact the study team

• Scott Barbuto, MD PhD · Phone: 12123054818

Official record on ClinicalTrials.gov — NCT07444333

Locations in the U.S.

Conditions

• Friedreich Ataxia
• Fatigue

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.